about
Obstetric antiphospholipid syndrome: early variations of angiogenic factors are associated with adverse outcomes.Polymorphisms of human placental alkaline phosphatase are associated with in vitro fertilization success and recurrent pregnancy loss.Soluble CD146, an innovative and non-invasive biomarker of embryo selection for in vitro fertilization.Antiphospholipid syndrome: looking for a refocusing.Neuropsychiatric presentations of antiphospholipid antibodies.Antiphospholid antibodies and the risk of pregnancy complications.Comparative incidence of pregnancy outcomes in thrombophilia-positive women from the NOH-APS observational study.Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study.Antiphospholipid antibodies are associated with positive screening for common mental disorders in women with previous pregnancy loss. The NOHA-PSY observational study.Atypical monoblasts with micronuclei.Successful Pregnancy under Fibrinogen Substitution with Heparin and Aspirin in a Woman with Dysfibrinogenemia Revealed by Placental AbruptionClinical value of automated fibrin generation markers in patients with septic shock: a SepsiCoag ancillary studyComparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational studyClinical efficacy of two cardiac troponin I assaysSystemic mastocytosisReliability of hemostasis biomarkers is affected by time-dependent intra-patient variabilityIncreased incidence of cancer in the follow-up of obstetric antiphospholipid syndrome within the NOH-APS cohortThe role of haemostasis in placenta-mediated complications
P50
Q33815975-F386F657-AA74-47A2-89A2-A1F2A6D5F153Q35057605-EBEDB06E-C582-4CA7-86DA-D09308611CFDQ36307573-56B01845-ACB9-4225-8ADC-031CE4798B51Q38085780-94B17326-2291-40F8-B3D8-FC3FF3C3CDE8Q38436403-7F648260-FF06-4C0E-922B-7BB68A605F27Q39163208-03BD28C4-4E80-4C5D-8CBB-07DFDD2CE7E0Q39319580-14626F7C-F18D-44C7-9860-5421835D001CQ43841492-B466F11A-9774-435F-ADD3-9FF49534AB10Q47716830-8E68EF81-C390-45A3-B92E-DE00F3237DA4Q48121059-F88A6D2B-865B-42E2-ACAF-EA246E9271B5Q57182312-32689FD1-929A-48B9-B8F6-AAEE49C4534BQ61853548-E3472B38-BC25-4D61-A66D-60A2137F2A20Q61853553-FA6093DF-AB71-4F0D-A010-618E6F66B177Q84319170-99D517EF-D3C9-42E4-A227-0CD46A08A6AAQ86501170-8BAA1983-9D6B-4894-A124-74F8072F231CQ89041033-218E3020-6129-40DE-BEED-244E8189FAA7Q92124996-E8879467-F04B-4DBC-8855-F25AFD464109Q93060974-D0E14D43-E925-4E1E-9FF0-E377998E86ED
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Sylvie Bouvier
@en
Sylvie Bouvier
@nl
type
label
Sylvie Bouvier
@en
Sylvie Bouvier
@nl
prefLabel
Sylvie Bouvier
@en
Sylvie Bouvier
@nl
P31
P496
0000-0001-8808-8841